CapBio announced that revenue for the first half of 2026 was 300 million yuan, a year-on-year decrease of 4.74%. Net profit attributable to shareholders of listed companies was 31.2621 million yuan, with a loss of 89.5914 million yuan in the same period last year, an increase of 134.89% over the previous year. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 12.134,400 yuan, with a loss of 95.6104 million yuan in the same period last year, an increase of 112.69% over the previous year. The company plans not to pay cash dividends, bonus shares, and not to use the Provident Fund to increase share capital.

CapBio announced that revenue for the first half of 2026 was 300 million yuan, a year-on-year decrease of 4.74%. Net profit attributable to shareholders of listed companies was 31.2621 million yuan, with a loss of 89.5914 million yuan in the same period last year, an increase of 134.89% over the previous year. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 12.134,400 yuan, with a loss of 95.6104 million yuan in the same period last year, an increase of 112.69% over the previous year. The company plans not to pay cash dividends, bonus shares, and not to use the Provident Fund to increase share capital.